There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Alpha-Synuclein


Brief Information

Name:Synuclein alpha
Target Synonym:Truncated Alpha Synuclein,Α-Synuclein,PARK1,SNCA,Synuclein Alpha,NACP,Parkinson Disease (Autosomal Dominant, Lewy Body) 4,Non-A4 Component Of Amyloid Precursor,Non A4 Component Of Amyloid Precursor,Non-A Beta Component Of AD Amyloid,Synuclein Alpha-140,I+
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
ALN-H82H8 Human Biotinylated Human Alpha-Synuclein Protein, His,Avitag™
ALN-H52H8 Human Human Alpha-Synuclein Protein, His Tag

Synonym Name



Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca2+ release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Affitope-PD01 PD-01A; Affitope-PD01; Affitope-PD01A; PD-01 (AFFiRiS) Phase 1 Clinical Affiris Parkinson Disease; Multiple System Atrophy; Neurodegenerative Diseases Details
Autologous bone marrow-derived mesenchymal stem cells (Corestem) CS-10BR05 Phase 1 Clinical Corestem Multiple System Atrophy Details
Lu AF-82422 (Lundbeck A/S) Phase 1 Clinical H. Lundbeck A/S, Genmab Parkinson Disease Details
Kenterin ENT-01; kenterin; Enterin-01 Phase 2 Clinical Enterin Constipation; Parkinson Disease; Dementia Details
Syneuro (Indus Biotech) Clinical Indus Biotech Pvt Ltd Parkinson Disease Details
PBT-434 PBT-434 Phase 1 Clinical Prana Biotechnology Parkinson Disease Details
UB-312 UB-312 Phase 1 Clinical United Neuroscience Parkinsonian Disorders; Parkinson Disease Details
Anle-138b Anle-138b Phase 1 Clinical Modag Gmbh Parkinson Disease; Multiple System Atrophy Details
MEDI-1341 MEDI-1341 Phase 1 Clinical Astrazeneca Pharmaceutical Co Ltd Parkinson Disease Details
NPT-189 NPT-189 Phase 1 Clinical Proclara Biosciences Immunoglobulin Light-chain Amyloidosis; Amyloidosis; Transthyretin amyloidosis Details
Prasinezumab PRX-002; RG-7935; NEOD-002; RO-7046015 Phase 2 Clinical Prothena Parkinson Disease Details
UCB-0599 UCB-0599 Phase 2 Clinical Ucb Sa Parkinson Disease Details

This web search service is supported by Google Inc.